Theralase Technologies (TLT) Q2 2025 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2025, rose 12% year-over-year to $310,933, with gross margin improving to 42% of revenue from 33% last year.

• Net loss increased 1% to $2,423,235, including $471,174 in non-cash charges such as amortization and stock-based compensation.

• Enrollment for Study II is nearly complete, with 96% of targeted patients treated and interim results showing a 61.4% complete response rate.

Financial highlights

• Cost of sales decreased 4% to $178,966, representing 58% of revenue, down from 67% last year.

• Gross margin increased 47% to $131,967.

• Selling expenses fell 5% to $139,011, while administrative expenses rose 10% to $995,333.

• Research and development expenses increased 1% to $1,460,447.

Outlook and guidance

• Enrollment for Study II expected to complete in 3Q2025, with data lock and regulatory submissions targeted for 4Q2026.